Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations.

ESMO open - 1 Oct 2024

Boscolo Bielo L, Guerini Rocco E, Trapani D, Zagami P, Taurelli Salimbeni B, Esposito A, Belli C, Crimini E, Venetis K, Munzone E, Fusco N, Criscitiello C, Marra A, Curigliano G

Abstract excerpt

BACKGROUND: Somatic genetic alterations of the estrogen receptor 1 gene (ESR1) are enriched in endocrine therapy-resistant, estrogen receptor-positive (ER+) metastatic breast cancer (mBC). Herein, we investigated and compared the clinical and genomic landscape of ESR1-mutant (ESR1MUT) and ESR1 wild type (ESR1WT) ER+/ human epidermal growth factor receptor 2 (HER2)- mBCs. METHODS: Clinical and genomic data were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Estrogen Receptor alpha

Share to Genomics

Share to Mutation

Share to Neoplasm Metastasis

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 39357123
DOI: 10.1016/j.esmoop.2024.103731
PMCID: PMC11480226

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations.PMID 39357123Read ↗

Characterization of ESR1 alterations in patients with breast and gynecologic cancers.Semantic proximity Read ↗

The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.Semantic proximity Read ↗

Molecular Characterization of ESR1 Variants in Breast CancerSemantic proximity Read ↗

Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer.Semantic proximity Read ↗

ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.Semantic proximity Read ↗

Molecular characterization of ESR1 variants in breast cancer.Semantic proximity Read ↗

ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients.Semantic proximity Read ↗

ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.Semantic proximity Read ↗

ESR1 activating mutations: From structure to clinical application.Semantic proximity Read ↗

Activating ESR1 mutations in hormone-resistant metastatic breast cancer.Semantic proximity Read ↗

Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.Semantic proximity Read ↗

ESR1 genetic alterations and their association with clinicopathologic characteristics in advanced breast cancer: a single academic institution experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.